Ix Therapeutics

Executive Summary

Ix Therapeutics is a Munich-based biotechnology company founded in 2017, dedicated to developing innovative biologic therapies that target challenging protein-protein interactions (PPIs) for cancer and other diseases. The company's platform addresses intracellular targets historically considered 'undruggable' by conventional small molecules or antibodies. Despite being in early stages with no disclosed funding or pipeline, Ix Therapeutics leverages a novel approach that could unlock new therapeutic avenues. The company has not yet reached clinical development, but its focus on PPIs positions it in a high-interest niche within biologics. Given the competitive landscape and early stage, Ix Therapeutics faces significant technical and funding risks, though success could yield first-in-class treatments.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement60% success
• Q4 2026Lead Program IND Filing or Preclinical Data Release40% success
• 2026Partnership or Licensing Deal with Pharma30% success